StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR - Free Report) in a report released on Friday. The firm issued a sell rating on the stock.
InspireMD Stock Up 2.4 %
Shares of NYSE NSPR traded up $0.06 on Friday, reaching $2.52. 15,304 shares of the company's stock traded hands, compared to its average volume of 53,024. The business's 50 day simple moving average is $2.84 and its two-hundred day simple moving average is $2.75. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.80. The company has a market cap of $74.82 million, a price-to-earnings ratio of -3.36 and a beta of 0.74.
Hedge Funds Weigh In On InspireMD
Several large investors have recently modified their holdings of NSPR. Courier Capital LLC bought a new stake in shares of InspireMD in the 1st quarter worth $81,000. Parkman Healthcare Partners LLC lifted its stake in InspireMD by 721.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company's stock valued at $2,248,000 after acquiring an additional 750,635 shares during the period. Schonfeld Strategic Advisors LLC grew its stake in shares of InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock worth $79,000 after acquiring an additional 18,233 shares during the period. Northern Trust Corp raised its holdings in shares of InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after purchasing an additional 24,452 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in InspireMD during the fourth quarter valued at approximately $27,000. Hedge funds and other institutional investors own 44.78% of the company's stock.
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Recommended Stories
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
